AUS
NZ
UK
CA
USA
IND
Carlyle Group (NASDAQ:CG) has agreed to purchase Baxter International's kidney-care unit, Vantive, for $3.8 billion. The acquisition, announced on Tuesday, is part of Baxter's strategy to reduce its substantial debt and streamline operations following its 2022 acquisition of Hill-Rom for $10.5 billion.
Deal Overview and Financial Impact
The sale of Vantive is expected to close by early 2025, with proceeds being used to help Baxter manage its long-term debt, which stood at $13.8 billion at the end of 2023. Last year, Baxter managed to reduce its debt by $2.8 billion after divesting its biopharma unit, and this transaction is expected to further ease its financial burdens.
Baxter initiated the process to carve out its kidney-care unit earlier this year as part of its efforts to refocus on its core operations. Vantive, which generated approximately $4.5 billion in revenue last year and employs over 23,000 people, has been a significant part of Baxter's portfolio. The sale marks a strategic move to rebalance its financial commitments.
Carlyle's Investment Strategy
Carlyle, one of the world's leading private equity firms with $435 billion in assets under management, partnered with Atmas Health, a healthcare investment platform formed by Carlyle in 2022, to secure the deal for Vantive. This acquisition is part of a broader trend in private equity, where firms have been increasingly active in deal-making, fueled by a rebound in leveraged buyout volumes. In the first half of 2024 alone, global leveraged buyout volumes surged 41% to $286 billion, reflecting the renewed confidence and activity in the market.
Carlyle has been particularly active in the healthcare sector and beyond. In July, the firm joined forces with KKR to acquire a $10 billion student loan portfolio from Discover Financial Services. Additionally, Carlyle is exploring the sale of StandardAero, a U.S. aircraft maintenance services provider, which could be valued at around $10 billion.
Advisory and Future Outlook
The deal has involved significant advisory input, with Perella Weinberg Partners, JPMorgan, and Sullivan & Cromwell advising Baxter, while Carlyle received counsel from Barclays, Goldman Sachs, and Kirkland & Ellis.
The acquisition of Vantive is a strategic move for Carlyle, aligning with its goal to expand its healthcare portfolio and capitalize on growth opportunities in the medical devices and services sector. For Baxter, the sale represents a significant step in managing its debt and refocusing on its core business areas.
